{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Sage Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"SAGE"},"Address":{"label":"Address","value":"215 FIRST STREET, CAMBRIDGE, Massachusetts, 02142, United States"},"Phone":{"label":"Phone","value":"+1 617 299-8380"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development."},"CompanyUrl":{"label":"Company Url","value":"https://www.sagerx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Barry E. Greene","title":"President, Chief Executive Officer & Director"},{"name":"Laura Gault","title":"Chief Medical Officer"},{"name":"Matt Lasmanis","title":"Chief Technology & Innovation Officer"},{"name":"Mike Quirk","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}